Clinical trial
Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy
NCT01195649 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy
- Lead sponsor
- Bayer
- Phase
- Observational
- Overall status
- Terminated
- Start date
- December 13, 2010
- Completion date
- August 31, 2012
- Enrollment
- 11 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.